Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Unit Gets FDA Priority Review for KTE-X19

share with twitter share with LinkedIn share with facebook
share via e-mail
02/10/2020 | 08:57am EDT

By Colin Kellaher

Gilead Sciences Inc. (GILD) on Monday said the U.S. Food and Drug Administration granted priority review to the biologics license application for its Kite unit's KTE-X19 for adults with relapsed or refractory mantle cell lymphoma, a rare form of non-Hodgkin lymphoma.

The Foster City, Calif., biopharmaceutical company said the filing is supported by data from a Phase 2 study in which 93% of patients responded to a single infusion of KTE-X19, including 67% who achieved a complete response.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months.

Gilead said the agency set a target action date of Aug. 10 for the application.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES
07:15aRecession Blue-Chips' Led the Way in Another Turbulent Week in Markets
DJ
06:51aGILEAD SCIENCES : Company - Kite Licenses Antibodies and Establishes Collaborati..
AQ
04/02GILEAD SCIENCES : Kite Licenses Antibodies and Establishes Collaboration With Te..
BU
03/30GILEAD : Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seve..
BU
03/28GILEAD SCIENCES : Revamps Process for Emergency Requests for Experimental Corona..
DJ
03/28GILEAD SCIENCES : Limits Access to Experimental Coronavirus Drug Due to High Dem..
DJ
03/25GILEAD SCIENCES : Withdraws Application for Orphan-Drug Status
DJ
03/25GILEAD SCIENCES : Statement on Request to Rescind Remdesivir Orphan Drug Designa..
PU
03/24GILEAD SCIENCES : Potential coronavirus treatment granted rare disease status
AQ
03/23GILEAD SCIENCES : Amendment to a previously filed SC TO-T
PU
More news
Financials (USD)
Sales 2020 22 418 M
EBIT 2020 10 567 M
Net income 2020 6 903 M
Finance 2020 6 946 M
Yield 2020 3,53%
P/E ratio 2020 14,2x
P/E ratio 2021 14,4x
EV / Sales2020 4,01x
EV / Sales2021 3,95x
Capitalization 96 919 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 75,48  $
Last Close Price 76,98  $
Spread / Highest target 16,9%
Spread / Average Target -1,95%
Spread / Lowest Target -24,7%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES18.47%94 124
VERTEX PHARMACEUTICALS10.60%61 693
REGENERON PHARMACEUTICALS32.83%53 154
WUXI APPTEC CO., LTD.1.90%21 017
GENMAB A/S-6.92%13 229
BEIGENE, LTD.-17.74%9 553